Built from a renowned program, aligned with a national strategy
The Precision Therapeutics AOE is a natural complement to the Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation’s program, in which individual pediatric subspecialty faculty members have been embedded within the division to prepare for careers in clinical and translational research. The AOE builds upon this model of integrated research and extends it from embedded individuals to include entire pediatric disciplines and subspecialties, weaving precision therapeutics into the very fabric of CRMI.
Led by J. Steven Leeder, PharmD, PhD, who previously served as director of Clinical Pharmacology, the AOE serves as an invaluable resource for faculty, research teams, and divisions interested in translational research, and complements the programs and initiatives of the Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation led by Jon Wagner, MD.
The integration of the precision therapeutics approach across all pediatric subspecialties at Children’s Mercy will lead to greater application of the GOLDILOKs (Genomic- and Ontogency-Linked Dose Individualization and cLinical Optimization for Kids) approach to care – ensuring that children receive a medication dose that is “just right” and optimized to meet their unique needs.
In addition, the mission and work of the Precision Therapeutics AOE aligns with the strategy and priorities of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the primary NIH Institute supporting research directed and mothers and children. Of the NICHD’s six research themes, the AOE is poised to address the need for safe and effective therapeutics and devices.